Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

PHASE3CompletedINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Parkinson's DiseaseDyskinesia
Interventions
DRUG

Sarizotan

Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.

DRUG

Placebo

Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.

Trial Locations (31)

10016

New York

11040

New Hyde Park

12401

New Hyde Park

15213

Pittsburgh

27705

Durham

30033

Decatur

32209

Jacksonville

32216

Jacksonville

32751

Maitland

33703

St. Petersburg

35233

Birmingham

35801

Huntsville

37027

Brentwood

48034

Southfield

50309

Des Moines

53233

Milwaukee

62702

Springfield

70112

New Orleans

73104

Oklahoma City

80113

Englewood

84403

South Ogden

92037

La Jolla

93030

Oxnard

95817

Sacramento

99204

Spokane

06810

Danbury

06030-1840

Farmington

60611-3078

Chicago

04074

Scarborough

02215

Boston

08818

Edison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia | Biotech Hunter | Biotech Hunter